Christopher Leamon
Chief Tech/Sci/R&D Officer at FUSN PHAR
Net worth: 255 880 $ as of 2024-04-29
Christopher Leamon active positions
| Companies | Position | Start | End |
|---|---|---|---|
| FUSN PHAR | Chief Tech/Sci/R&D Officer | 2021-11-01 | - |
Career history of Christopher Leamon
Former positions of Christopher Leamon
| Companies | Position | Start | End |
|---|---|---|---|
Advanced Accelerator Applications USA, Inc.
 Advanced Accelerator Applications USA, Inc. Medical SpecialtiesHealth Technology Part of Novartis AG, Advanced Accelerator Applications USA, Inc. develops, produces, and commercializes MNM diagnostic and therapeutic products. The company is based in New York, NY. | Corporate Officer/Principal | - | - |
| Glaxo Wellcome Plc | Corporate Officer/Principal | - | - |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
| ENDOCYTE, INC. | Chief Tech/Sci/R&D Officer | 1999-01-31 | - |
Training of Christopher Leamon
| Baldwin-Wallace College | Undergraduate Degree |
| Purdue University | Doctorate Degree |
Statistics
International
| United States | 6 |
| United Kingdom | 2 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| FUSN PHAR | Health Technology |
| Private companies | 4 |
|---|---|
| Glaxo Wellcome Plc | Health Technology |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Advanced Accelerator Applications USA, Inc.
Advanced Accelerator Applications USA, Inc. Medical SpecialtiesHealth Technology Part of Novartis AG, Advanced Accelerator Applications USA, Inc. develops, produces, and commercializes MNM diagnostic and therapeutic products. The company is based in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Christopher Leamon
- Experience
